Lab21 is expanding its clinical diagnostics portfolio with the introduction of a new service to identify the two most common causes of fungal pneumonia. The CE-marked FXGTM:RESP (ASP+) test, developed by UK diagnostics company Myconostica, will identify infections caused by Aspergillus and Pneumocystis, which account for over 95% of cases of fungal pneumonia and could radically alter the diagnosis of fungal disease.
Your partner for equipment and consumables for medicine and science
Sarstedt, one of the world's leading providers of laboratory and medical equipment, develops, manufactures and sells equipment and consumables in the field of medicine and science.
Founded in 1961, the company has continued to grow to the point where it now employs a...
Hyatt Regency, Orlando, FL
3-5 November, 2025
America Square Conference Centre, London, EC3N 2LB.
4 - 5 November, 2024
Messe Dusseldorf
11-14 November, 2024
SEC Arena, Glasgow
14 November, 2024
Hyatt Regency, Vancouver, Canada
19-23 November, 2024
